Published in Antimicrob Agents Chemother on July 11, 2011
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol (2013) 1.34
A Medicinal Herb Scutellaria lateriflora Inhibits PrP Replication in vitro and Delays the Onset of Prion Disease in Mice. Front Psychiatry (2012) 0.75
Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature (1997) 15.73
The same prion strain causes vCJD and BSE. Nature (1997) 12.49
Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci (2003) 8.44
Scrapie prions aggregate to form amyloid-like birefringent rods. Cell (1983) 7.92
Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol (1987) 7.05
Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J (1996) 6.66
Prion diseases of humans and animals: their causes and molecular basis. Annu Rev Neurosci (2001) 6.61
Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet (2001) 5.57
Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol (1993) 3.07
Porphyrin and phthalocyanine antiscrapie compounds. Science (2000) 2.54
BSE transmission to macaques. Nature (1996) 2.32
Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature (2003) 2.31
The prion diseases. Brain Pathol (1998) 2.20
New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol (2003) 2.09
Potent inhibition of scrapie-associated PrP accumulation by congo red. J Neurochem (1992) 2.00
Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol (2004) 1.97
Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology (2004) 1.82
Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines. Proc Natl Acad Sci U S A (1998) 1.80
Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A (1997) 1.79
Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science (1997) 1.70
Scrapie strains maintain biological phenotypes on propagation in a cell line in culture. EMBO J (2001) 1.50
Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology (2004) 1.45
Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol (1995) 1.42
Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J Gen Virol (1987) 1.39
Geldanamycin induces Hsp70 and prevents alpha-synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun (2004) 1.30
Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Bioorg Med Chem Lett (2002) 1.29
A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorg Med Chem Lett (2007) 1.27
An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates. J Virol (2005) 1.22
Unsuccessful intraventricular pentosan polysulphate treatment of variant Creutzfeldt-Jakob disease. Acta Neurochir (Wien) (2006) 1.21
Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med (2007) 1.18
A comparative study of immunohistochemical methods for detecting abnormal prion protein with monoclonal and polyclonal antibodies. J Comp Pathol (2000) 1.16
Specific inhibition of pathological prion protein accumulation by small interfering RNAs. J Cell Sci (2003) 1.13
Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol (2003) 1.12
Human prion diseases and bovine spongiform encephalopathy (BSE). Hum Mol Genet (1997) 1.11
Strain typing of German transmissible spongiform encephalopathies field cases in small ruminants by biochemical methods. J Vet Med B Infect Dis Vet Public Health (2005) 1.04
Synthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against monoamine oxidase. J Med Chem (2004) 1.03
Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie. Neurosci Lett (2005) 1.02
A porphyrin increases survival time of mice after intracerebral prion infection. Antimicrob Agents Chemother (2006) 0.99
Chaperones and aging: role in neurodegeneration and in other civilizational diseases. Neurochem Int (2002) 0.96
The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS One (2008) 0.96
Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet (2003) 0.96
Long term survival in a patient with variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulphate. J Neurol Neurosurg Psychiatry (2007) 0.95
Amino acid sequence and prion strain specific effects on the in vitro and in vivo convertibility of ovine/murine and bovine/murine prion protein chimeras. Biochim Biophys Acta (2006) 0.95
Bovine spongiform encephalopathy (BSE) and its epidemiology. Br Med Bull (2003) 0.93
Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine (2005) 0.93
Evaluation of new cell culture inhibitors of protease-resistant prion protein against scrapie infection in mice. J Gen Virol (2004) 0.88
Oral pravastatin prolongs survival time of scrapie-infected mice. J Gen Virol (2009) 0.86
The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease. Arch Neurol (1983) 0.84
Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir. Lancet (1984) 0.83
Mefloquine, an antimalaria drug with antiprion activity in vitro, lacks activity in vivo. J Virol (2006) 0.82
Synergistic and strain-specific effects of bovine spongiform encephalopathy and scrapie prions in the cell-free conversion of recombinant prion protein. J Gen Virol (2006) 0.82
Acyclovir in Creutzfeldt-Jakob disease. Lancet (1984) 0.81
Antigenic features of prion proteins of sheep and of other mammalian species. J Immunol Methods (1997) 0.80
Creutzfeldt-Jakob disease. Lancet (1996) 0.80
Scrapie-associated PrP accumulation and its inhibition: revisiting the amyloid-glycosaminoglycan connection. Ann N Y Acad Sci (1994) 0.79
Effect of amphotericin B on wild-type and mutated prion proteins in cultured cells: putative mechanism of action in transmissible spongiform encephalopathies. J Neurochem (2000) 0.78
[Caffeine, adenosine receptors, memory and Alzheimer disease]. Med Clin (Barc) (2008) 0.77
[What are the prospects for pharmacological treatment of prion disease?]. Therapie (2002) 0.76
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol (2007) 6.58
The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science (2013) 6.34
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol (2007) 5.02
A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain (2009) 4.40
Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci (2007) 3.16
TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol (2007) 2.97
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol (2009) 2.76
Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat Genet (2011) 2.76
Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol (2009) 2.68
Genetic prion disease: the EUROCJD experience. Hum Genet (2005) 2.64
Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest (2002) 2.47
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Chaperonin TRiC promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Mol Cell (2006) 2.16
ALDH1A1 is a marker of astrocytic differentiation during brain development and correlates with better survival in glioblastoma patients. Brain Pathol (2012) 2.14
Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J (2010) 2.12
Atypical BSE in Germany--proof of transmissibility and biochemical characterization. Vet Microbiol (2006) 2.10
TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol (2008) 2.02
TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol (2007) 2.02
Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci (2006) 1.99
Conversion of the BASE prion strain into the BSE strain: the origin of BSE? PLoS Pathog (2007) 1.97
Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep (2002) 1.91
Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol (2013) 1.82
The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J (2011) 1.80
Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol (2008) 1.78
FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain (2011) 1.76
Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol (2004) 1.74
Scrapie Agent (Strain 263K) can transmit disease via the oral route after persistence in soil over years. PLoS One (2007) 1.72
Highly bovine spongiform encephalopathy-sensitive transgenic mice confirm the essential restriction of infectivity to the nervous system in clinically diseased cattle. J Infect Dis (2005) 1.70
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer (2007) 1.67
Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun (2009) 1.63
Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol (2013) 1.59
Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem (2008) 1.56
Epizootic emergence of Usutu virus in wild and captive birds in Germany. PLoS One (2012) 1.55
Isolation of usutu virus in Germany. Am J Trop Med Hyg (2011) 1.55
Identification of differentially expressed genes in scrapie-infected mouse brains by using global gene expression technology. J Virol (2004) 1.50
Effects of different experimental conditions on the PrPSc core generated by protease digestion: implications for strain typing and molecular classification of CJD. J Biol Chem (2004) 1.50
Lithium induces clearance of protease resistant prion protein in prion-infected cells by induction of autophagy. J Neurochem (2009) 1.50
FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging (2007) 1.47
State-of-the-art review of goat TSE in the European Union, with special emphasis on PRNP genetics and epidemiology. Vet Res (2009) 1.46
Autophagy induction by trehalose counteracts cellular prion infection. Autophagy (2009) 1.46
Target-dependent specification of the neurotransmitter phenotype: cholinergic differentiation of sympathetic neurons is mediated in vivo by gp 130 signaling. Development (2005) 1.44
Diagnosis of the first cases of scrapie in Poland. Vet J (2009) 1.44
Analysis of sequence variability of the bovine prion protein gene (PRNP) in German cattle breeds. Neurogenetics (2004) 1.43
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity. J Urol (2013) 1.43
Characterization of truncated forms of abnormal prion protein in Creutzfeldt-Jakob disease. J Biol Chem (2008) 1.40
Atypical scrapie prions from sheep and lack of disease in transgenic mice overexpressing human prion protein. Emerg Infect Dis (2013) 1.38
Epidemiological and genetical differences between classical and atypical scrapie cases. Vet Res (2006) 1.38
Multiple amino acid residues within the rabbit prion protein inhibit formation of its abnormal isoform. J Virol (2003) 1.35
Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. Brain (2006) 1.35
Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway. J Neurosci (2009) 1.35
Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem (2002) 1.35
Ultrafast spectroscopy reveals subnanosecond peptide conformational dynamics and validates molecular dynamics simulation. Proc Natl Acad Sci U S A (2002) 1.34
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol (2013) 1.34
Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med (2006) 1.33
The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem (2004) 1.33
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS One (2011) 1.32
Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification. Acta Neuropathol (2009) 1.32
European surveillance for West Nile virus in mosquito populations. Int J Environ Res Public Health (2013) 1.31
Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiol Aging (2012) 1.30
Autocatalytic self-propagation of misfolded prion protein. Proc Natl Acad Sci U S A (2004) 1.30
Prions spread via the autonomic nervous system from the gut to the central nervous system in cattle incubating bovine spongiform encephalopathy. J Gen Virol (2007) 1.30
Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors. Int J Cancer (2012) 1.30
Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathol (2012) 1.29
Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol (2010) 1.29
TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol (2008) 1.28
Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol (2008) 1.28
Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol (2009) 1.27
Neuronal accumulation of abnormal prion protein in sheep carrying a scrapie-resistant genotype (PrPARR/ARR). J Gen Virol (2004) 1.27
Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice. Neurobiol Aging (2006) 1.26
Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol (2010) 1.26
The role of the octarepeat region in neuroprotective function of the cellular prion protein. Brain Pathol (2007) 1.25
Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res (2011) 1.23
Seroprevalence study in forestry workers from eastern Germany using novel genotype 3- and rat hepatitis E virus-specific immunoglobulin G ELISAs. Med Microbiol Immunol (2011) 1.22
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Classic scrapie in sheep with the ARR/ARR prion genotype in Germany and France. Emerg Infect Dis (2007) 1.20
Generation of genuine prion infectivity by serial PMCA. Vet Microbiol (2007) 1.19
Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta Neuropathol (2004) 1.19
MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain (2005) 1.18
Conversion efficiency of bank vole prion protein in vitro is determined by residues 155 and 170, but does not correlate with the high susceptibility of bank voles to sheep scrapie in vivo. J Biol Chem (2006) 1.17
The yeast Sup35NM domain propagates as a prion in mammalian cells. Proc Natl Acad Sci U S A (2008) 1.16
The prion protein requires cholesterol for cell surface localization. Mol Cell Neurosci (2005) 1.16
Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. Arch Neurol (2006) 1.15
Absence of heterogeneous nuclear ribonucleoproteins and survival motor neuron protein in TDP-43 positive inclusions in frontotemporal lobar degeneration. Acta Neuropathol (2007) 1.14
PRNP promoter polymorphisms are associated with BSE susceptibility in Swiss and German cattle. BMC Genet (2007) 1.13
Chronic wasting disease. Top Curr Chem (2011) 1.12